Latest

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi

Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC

May 04 2026

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

INDUSTRY SYMPOSIUM

S. PetersA. AddeoM. DasH. HorinouchiT. SequeiraC. LovlyD. PlanchardS. PatelA. CortelliniL. ByersG. MountziosA. Dingemans

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

Best Practices in Managing Adverse Events with ADCs in NSCLC

} 18 min

N. Girard

From Our Annual Summit

ILCS Sessions

Nov132026

ILCS 2026

The International Lung Cancer Summit 2026

Learn more about the event

ILCS 2025

SCLC

Reshaping Approaches in SCLC with the Latest Advances in LS- and ES-Disease

} 34 min

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

ILCS 2025

Immunotherapies

The Role of IO Added to Chemoradiation in Unresectable Stage III NSCLC

} 28 min

Tailoring IO in Res. NSCLC: Personalized Approaches for Improved Outcomes

} 36 min

The ADC Revolution in Lung Cancer: New Targets, New Opportunities

} 27 min

DEBATE: Which Is the Better Choice in EGFR+ Advanced NSCLC?

} 31 min

Actionable Genomic Alterations – Including HER2 and MET

} 26 min

S. Saw

Expert Insights

Webinars

Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin

Dec 18 2025

Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck

Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard

Jul 10 2025

O. GautschiJ. NaidooN. Girard

Targeted Therapies in NSCLC

} 1h 30 min

IO in NSCLC by Solange Peters, Jordi Remon, Patrick Forde

Jun 25 2025

P. FordeJ. RemonS. Peters

Immunotherapies in NSCLC

} 1h 47 min

SCLC by Solange Peters, Giannis Mountzios, Jacob Sands

Jun 17 2025

G. MountziosJ. SandsS. Peters

SCLCImmunotherapies

Small Cell Lung Cancer

} 1h 35 min

The Reading Room

Articles & Research

Sep 09 2026

HARMONi primary analysis reports 6.8 against 4.4 months PFS for ivonescimab plus chemotherapy after EGFR TKI progression

Sep 08 2026

Pleural metastases carried worse two-year survival than contralateral lung metastases in stage M1a NSCLC

L. Hendriks

Sep 04 2026

TARGETED THERAPIES

An EGFR-SHC1 fusion resists EGFR inhibitors through its non-kinase partner

X. Le

Sep 03 2026

Akeso reports an OS benefit for ivonescimab over pembrolizumab in PD-L1-positive NSCLC

Sep 02 2026

Resectable NSCLCTargeted Therapies

AI-HOPE registry recruits 920 patients to build machine-learning models for metastatic NSCLC outcomes

R. FerraraL. Hendriks

Aug 31 2026

TARGETED THERAPIES

Adjuvant alectinib held its advantage in ALINA’s Asia subgroup, on 31 events and immature survival data

International panel sets 55 consensus recommendations for managing Dato-DXd side effects in NSCLC

S. Saw

Aug 27 2026

ADCs, IMMUNOTHERAPIES, TARGETED THERAPIES

Advanced NSCLCADCsImmunotherapies

Two EORTC questionnaires cover the common side effects in NSCLC labels, and miss 62 rarer ones

J. RemonR. Ferrara

Industry Sponsored

Featured Sessions

Jul 20 2026

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi

May 04 2026

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.